ECSP11011437A - Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos - Google Patents
Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismosInfo
- Publication number
- ECSP11011437A ECSP11011437A EC2011011437A ECSP11011437A ECSP11011437A EC SP11011437 A ECSP11011437 A EC SP11011437A EC 2011011437 A EC2011011437 A EC 2011011437A EC SP11011437 A ECSP11011437 A EC SP11011437A EC SP11011437 A ECSP11011437 A EC SP11011437A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- kinases
- indications
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen compuestos y sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos, formas de los mismos y usos de los mismos. En algunos aspectos y formas de realización, los compuestos descriptos o sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos y formas de los mismos son activos en cada una de las proteína quinasas BRaf y c-Raf-1, y también pueden ser activos en cualquiera, o ambas, de las proteínas quinasas A-Raf y B-Raf V600E. También se describen métodos de uso de los mismos para tratar enfermedades y condiciones, incluyendo melanoma, cáncer colorrectal, cáncer de tiroides, cáncer ovárico y cáncer del tracto biliar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17605409P | 2009-05-06 | 2009-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011437A true ECSP11011437A (es) | 2011-12-30 |
Family
ID=42236712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011437A ECSP11011437A (es) | 2009-05-06 | 2011-11-01 | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120122860A1 (es) |
| EP (2) | EP2427462A1 (es) |
| JP (2) | JP2012526128A (es) |
| KR (1) | KR20140014386A (es) |
| CN (1) | CN102459262A (es) |
| AR (1) | AR076749A1 (es) |
| AU (1) | AU2010246005A1 (es) |
| BR (1) | BRPI1013843A2 (es) |
| CA (1) | CA2759997A1 (es) |
| CL (1) | CL2011002739A1 (es) |
| CR (1) | CR20110562A (es) |
| EC (1) | ECSP11011437A (es) |
| IL (1) | IL215908A0 (es) |
| MA (1) | MA34042B1 (es) |
| MX (1) | MX2011011737A (es) |
| NI (1) | NI201100189A (es) |
| NO (1) | NO20111508A1 (es) |
| PE (1) | PE20120518A1 (es) |
| RU (1) | RU2011149485A (es) |
| SG (1) | SG175810A1 (es) |
| TW (1) | TW201041888A (es) |
| WO (2) | WO2010129570A1 (es) |
| ZA (1) | ZA201108124B (es) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2395004T3 (en) * | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| HUE027598T2 (en) | 2009-04-03 | 2016-10-28 | Hoffmann La Roche | Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
| JP2013511541A (ja) * | 2009-11-18 | 2013-04-04 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物および方法、ならびにその適応 |
| KR20120112623A (ko) * | 2009-12-23 | 2012-10-11 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2012075210A2 (en) * | 2010-12-01 | 2012-06-07 | Niiki Pharma Inc. | Method for treating refractory cancer |
| US20140024539A1 (en) * | 2011-02-02 | 2014-01-23 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| TWI558702B (zh) * | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| WO2012138809A1 (en) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
| EP2709622A4 (en) | 2011-05-17 | 2015-03-04 | Plexxikon Inc | CINEMA MODULATION AND INDICATIONS THEREFOR |
| CN107245056A (zh) * | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
| CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
| EP2755657B1 (en) | 2011-09-14 | 2017-11-29 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| JP6013029B2 (ja) * | 2012-05-25 | 2016-10-25 | 千葉県 | 抗癌剤 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN104470920A (zh) * | 2012-07-03 | 2015-03-25 | 通益制药有限公司 | 固态形式的维罗菲尼胆碱盐 |
| DE102012016908A1 (de) * | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| CN104981247A (zh) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| CN105712992B (zh) * | 2012-09-29 | 2018-10-26 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
| US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US9676778B2 (en) | 2012-11-20 | 2017-06-13 | Principia Biopharma Inc. | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| MX2015009270A (es) * | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| CN105008356A (zh) * | 2013-03-14 | 2015-10-28 | 拉蒂奥法姆有限责任公司 | 固态形式的盐酸威罗菲尼 |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| HRP20181392T1 (hr) | 2013-03-15 | 2018-10-19 | Plexxikon Inc. | Heterociklični spojevi i njihova uporaba |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| AU2014274093B2 (en) | 2013-05-30 | 2018-11-08 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015075749A1 (en) * | 2013-11-22 | 2015-05-28 | Laurus Labs Private Limited | Novel processes for the preparation of vemurafenib |
| CZ2013943A3 (cs) | 2013-11-27 | 2015-06-03 | Zentiva, K.S. | Krystalické formy vemurafenibu |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2015238305B2 (en) | 2014-03-26 | 2020-06-18 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| JO3695B1 (ar) | 2015-02-10 | 2020-08-27 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CZ2015250A3 (cs) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| EP4071149A3 (en) | 2015-09-21 | 2023-01-25 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
| CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
| KR102703498B1 (ko) | 2015-09-23 | 2024-09-04 | 얀센 파마슈티카 엔브이 | 신규 화합물 |
| CN108368110A (zh) | 2015-12-07 | 2018-08-03 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| KR20190017913A (ko) * | 2016-06-13 | 2019-02-20 | 케모센트릭스, 인크. | 췌장 암을 치료하는 방법 |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| EP4134080B1 (en) | 2016-11-23 | 2024-11-13 | ChemoCentryx, Inc. | Ccr2 inhibitors for use in treating renal diseases |
| AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| JP2020511467A (ja) | 2017-03-20 | 2020-04-16 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形 |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| WO2019023198A1 (en) | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | FORMULATION OF A COMPOUND MODULATING KINASES |
| US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| TWI803530B (zh) | 2017-10-27 | 2023-06-01 | 美商普雷辛肯公司 | 調節激酶之化合物之調配物 |
| AU2019207491A1 (en) * | 2018-01-10 | 2020-07-30 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
| SG11202007143UA (en) | 2018-01-31 | 2020-08-28 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
| WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| IL279641B2 (en) * | 2018-07-16 | 2024-04-01 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| FI4073065T3 (fi) | 2019-12-10 | 2025-04-16 | Hoffmann La Roche | Uusia metyylikinatsolinonijohdannaisia |
| JP7639008B2 (ja) | 2020-01-15 | 2025-03-04 | ヘパリジェニックス ゲーエムベーハー | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 |
| BR112022021920A2 (pt) | 2020-04-29 | 2023-01-17 | Plexxikon Inc | Síntese de compostos heterocíclicos |
| CA3173629A1 (en) | 2020-06-19 | 2021-12-13 | Cosimo Dolente | Braf degraders |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277551B1 (en) * | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| DE102005034406A1 (de) | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | Neue Salze von Rosiglitazon |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20081581A1 (es) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| US20100190777A1 (en) * | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
-
2010
- 2010-04-30 TW TW099113997A patent/TW201041888A/zh unknown
- 2010-05-04 US US13/318,760 patent/US20120122860A1/en not_active Abandoned
- 2010-05-04 US US12/773,798 patent/US8198273B2/en active Active
- 2010-05-04 MA MA34424A patent/MA34042B1/fr unknown
- 2010-05-04 MX MX2011011737A patent/MX2011011737A/es not_active Application Discontinuation
- 2010-05-04 JP JP2012509907A patent/JP2012526128A/ja active Pending
- 2010-05-04 CA CA2759997A patent/CA2759997A1/en not_active Abandoned
- 2010-05-04 BR BRPI1013843A patent/BRPI1013843A2/pt not_active IP Right Cessation
- 2010-05-04 KR KR1020117029018A patent/KR20140014386A/ko not_active Withdrawn
- 2010-05-04 PE PE2011001867A patent/PE20120518A1/es not_active Application Discontinuation
- 2010-05-04 RU RU2011149485/02A patent/RU2011149485A/ru not_active Application Discontinuation
- 2010-05-04 JP JP2012509906A patent/JP2012526127A/ja active Pending
- 2010-05-04 EP EP10717408A patent/EP2427462A1/en not_active Withdrawn
- 2010-05-04 WO PCT/US2010/033576 patent/WO2010129570A1/en not_active Ceased
- 2010-05-04 SG SG2011078979A patent/SG175810A1/en unknown
- 2010-05-04 AU AU2010246005A patent/AU2010246005A1/en not_active Abandoned
- 2010-05-04 CN CN2010800305090A patent/CN102459262A/zh active Pending
- 2010-05-04 WO PCT/US2010/033571 patent/WO2010129567A1/en not_active Ceased
- 2010-05-04 EP EP10717980A patent/EP2427433A1/en not_active Withdrawn
- 2010-05-05 AR ARP100101517A patent/AR076749A1/es not_active Application Discontinuation
-
2011
- 2011-10-25 IL IL215908A patent/IL215908A0/en unknown
- 2011-10-26 CR CR20110562A patent/CR20110562A/es unknown
- 2011-11-01 EC EC2011011437A patent/ECSP11011437A/es unknown
- 2011-11-03 NO NO20111508A patent/NO20111508A1/no not_active Application Discontinuation
- 2011-11-03 CL CL2011002739A patent/CL2011002739A1/es unknown
- 2011-11-03 NI NI201100189A patent/NI201100189A/es unknown
- 2011-11-04 ZA ZA2011/08124A patent/ZA201108124B/en unknown
-
2012
- 2012-06-07 US US13/491,480 patent/US20120245174A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100286142A1 (en) | 2010-11-11 |
| CR20110562A (es) | 2012-02-09 |
| ZA201108124B (en) | 2014-04-30 |
| MX2011011737A (es) | 2011-12-08 |
| WO2010129570A1 (en) | 2010-11-11 |
| US20120245174A1 (en) | 2012-09-27 |
| AU2010246005A1 (en) | 2011-12-01 |
| AR076749A1 (es) | 2011-07-06 |
| EP2427433A1 (en) | 2012-03-14 |
| CA2759997A1 (en) | 2010-11-11 |
| RU2011149485A (ru) | 2013-06-20 |
| JP2012526128A (ja) | 2012-10-25 |
| TW201041888A (en) | 2010-12-01 |
| CL2011002739A1 (es) | 2012-04-09 |
| KR20140014386A (ko) | 2014-02-06 |
| WO2010129567A1 (en) | 2010-11-11 |
| MA34042B1 (fr) | 2013-03-05 |
| PE20120518A1 (es) | 2012-05-24 |
| BRPI1013843A2 (pt) | 2016-04-12 |
| US8198273B2 (en) | 2012-06-12 |
| US20120122860A1 (en) | 2012-05-17 |
| NO20111508A1 (no) | 2011-12-02 |
| JP2012526127A (ja) | 2012-10-25 |
| CN102459262A (zh) | 2012-05-16 |
| IL215908A0 (en) | 2012-01-31 |
| NI201100189A (es) | 2012-01-11 |
| SG175810A1 (en) | 2011-12-29 |
| EP2427462A1 (en) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100189A (es) | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos | |
| UY31829A (es) | Compuestos y métodos para modulación de cinasas, e indicaciones para ello | |
| NI201100168A (es) | Derivados de pirrolo [2,3-b] piridina para la inhibición de quinasas raf | |
| CO6551689A2 (es) | Compuestos y métodos para la modulación de cinasas, e indicadores para ello | |
| CR10734A (es) | Anticuerpos e inmunoconjugados y sus usos | |
| AR060978A1 (es) | Anticuerpos e inmunoconjugados y sus usos | |
| CR10372A (es) | Anticuerpos anti-tat226 e inmunoconjugados | |
| AR076105A1 (es) | Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa | |
| CL2017002110A1 (es) | Nuevos conjugados de anticuerpos y usos de los mismos (divisional solicitud 201502357) | |
| MX377339B (es) | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. | |
| BRPI1013771A2 (pt) | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." | |
| CR20130374A (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos | |
| CO6270257A2 (es) | Derivados de piridazinona | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| MX385217B (es) | Antagonistas de actriib y dosificación y usos de los mismos. | |
| HN2005029978A (es) | Formulaciones | |
| PH12013501837A1 (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases | |
| UY33346A (es) | Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma | |
| MX2009009117A (es) | Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2. | |
| EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
| BRPI0821489A2 (pt) | Tratamento de degeneração do disco intervetebral com o uso de células derivadas de tecido de cordão umbilical humano | |
| BRPI0511396A (pt) | derivados de retinal e métodos para uso no tratamento de enfermidades visuais | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина |